Benefits of oral Polypodium Leucotomos extract in MM high-risk patients

Journal of the European Academy of Dermatology and Venereology

Volumn 27, Issue 9, 2013, Pages 1095-1100

  Aguilera, P ^a   Carrera, C ^a   Puig Butille, J A ^a,d   Badenas, C ^a   Lecha, M ^a   Gonzalez S ^b,c   Malvehy, J ^a,d   Puig, S ^a,d  

^a UNIVERSITY OF BARCELONA   (Spain)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; GENOMIC DNA; MELANOCORTIN 1 RECEPTOR; POLYPODIUM LEUCOTOMOS EXTRACT;

ADULT; ARTICLE; BLOOD SAMPLING; DYSPLASTIC NEVUS; ERYTHEMA; EYE COLOR; FAMILIAL ATYPICAL MULTIPLE MOLE MELANOMA SYNDROME; FEMALE; GENE MUTATION; GENETIC POLYMORPHISM; HAIR COLOR; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; PHENOTYPE; PHOTOSENSITIVITY; PRIORITY JOURNAL; RISK FACTOR; SINGLE DRUG DOSE; SKIN CANCER; SKIN COLOR; TREATMENT RESPONSE; ULTRAVIOLET B RADIATION;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; PHYTOTHERAPY; PLANT EXTRACTS; POLYMORPHISM, GENETIC; POLYPODIUM; RISK FACTORS; SKIN NEOPLASMS; YOUNG ADULT;

EID: 84881168625     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2012.04659.x     Document Type: Article

References (31)

1. Bataille V,. Genetic epidemiology of MM. Eur J Cancer 2003; 39: 1341-1347.
2. Bataille V, Winnett A, Sasieni P, Newton Bishop JA, Cuzick J,. Exposure to the sun and sunbeds and the risk of cutaneous MM in the UK: a case-control study. Eur J Cancer 2004; 40: 429-435.
3. Rigel DS, Friedman RJ, Kopf AW,. The incidence of malignant MM in the United States: issues as we approach the 21st century. J Am Acad Dermatol 1999; 34: 839-847.
4. Gilchrest B, Eller MS, Geller AC, Yaar M,. The pathogenesis of MM induced by ultraviolet radiation. N Engl J Med 1999; 340: 1341-1348.
5. Naldi L, Imberti GL, Parazzini F, Gallus S, La Vecchia C,. Pigmentary traits, modalities of sun reaction, history of sunburns, and melanocytic nevi as risk factors for cutaneous malignant MM in the Italian population. Cancer 2000; 88: 2703-2710.
6. Walker SL, Hawk JLM, Young AR,. Acute and chronic effects of ultraviolet radiation on the skin. In:, Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, eds. Fitzpatrick's Dermatology in General Medicine, 6th edn. McGraw-Hill Companies Inc, New York, NY, 2003: 1275-1282.
7. Horvath A, Alvarado F, Szocs J, de Alvardo ZN, Padilla G,. Metabolic effects of calagualine, an antitumoral saponine of Polypodium leucotomos. Nature 1967; 214: 1256-1258.
8. Alcaraz MV, Pathak MA, Rius F, Kollias N, Gonzalez S,. An extract of Polypodium leucotomos appears to minimize certain photoaging changes in a hairless albino mouse animal model. A pilot study. Photodermatol Photoimmunol Photomed 1999; 15: 120-126.
9. Zattra E, Coleman C, Arad S, et al. Polypodium leucotomos extract decreases UV-induced Cox-2 expression and inflammation, enhances DNA repair, and decreases mutagenesis in hairless mice. Am J Pathol 2009; 175: 1952-1261.
10. González S, Pathak MA, Cuevas J, Villarrubia VG, Fitzpatrick TB,. Topical or Oral treatment of an extract of Polypodium leucotomos prevents acute sunburn and psoralen-induced phototoxic reactions as well as depletion of Langerhans cells in human skin. Photodermatol Photoimmunol Photomed 1997; 13: 50-60.
11. Middelkamp-Hup MA, Pathak MA, Parrado C, et al. Oral Polypodium leucotomos extract decreases ultraviolet-induced damage of human skin. J Am Acad Dermatol 2004; 51: 910-918.
12. Middelkamp-Hup MA, Pathak MA, Parrado C, et al. Orally administered Polypodium leucotomos extract decreases psoralen-UVA-induced phototoxicity, pigmentation, and damage of human skin. J Am Acad Dermatol 2004; 50: 41-49.
13. Villa A, Viera MH, Amini S, et al. Decrease of ultraviolet A light-induced 'common deletion' in healthy volunteers after oral Polypodium leucotomos extract supplement in a randomized clinical trial. J Am Acad Dermatol 2009; 62: 511-513.
14. Nelson AA, Tsao H,. MM and genetics. Clin Dermatol 2009; 27: 46-52 (Review).
15. Berwick M, Orlow I, Hummer AJ, et al. The prevalence of CDKN2A germ-line mutations and relative risk for cutaneous malignant MM: an international population-based study. Cancer Epidemiol Biomarkers Prev 2006; 15: 1520-1525.
16. Zuo L, Weger J, Yang Q, et al. Germline mutations in the p16INK4a binding domain of CDK4 in familial MM. Nat Genet 1996; 12: 97-99.
17. Box NF, Wyeth JR, O'Gorman LE, Martin NG, Stum RA,. Characterization of melanocyte-stimulating hormona receptor variant alleles in twins with red hair. Hum Mol Genet 1997; 6: 1891-1897.
18. Palmer JS, Duffy DL, Box NF, et al. Melanocortin-1 receptor polymorphisms and risk of MM: is the association explained solely by pigmentation phenotype? Am J Hum Genet 2000; 66: 176-186.
19. Valverde P, Healy E, Sikkink S, et al. The Asp84Glu variant of the melanocortin 1 receptor (MC1R) is associated with MM. Hum Mol Genet 1996; 5: 1663-1666.
20. Valverde P, Healy E, Jackson I, Rees JL, Thody AJ,. Variants of the melanocyte-stimulating hormone receptor gene are associated with red hair and fair skin in humans. Nat Genet 1995; 11: 328-330.
21. van der Velden PA, Sandkuijl LA, Bergman W, et al. Melanocortin-1 receptor variant R151C modifies MM risk in Dutch families with MM. Am J Hum Genet 2001; 69: 774-779.
22. Box NF, Duffy DL, Chen W, et al. MC1R genotype modifies risk of MM in families segregating CDKN2A mutations. Am J Hum Genet 2001; 69: 765-773.
23. Scott MC, Suzuki I, Abdel-Malek ZA,. Regulation of the human melanocortin 1 receptor expression in epidermal melanocytes by paracrine and endocrine factors and by ultraviolet radiation. Pigment Cell Res 2002; 15: 433-439.
24. Puig S, Malvehy J, Badenas C, et al. Role of the CDKN2A locus in patients with multiple primary MMs. J Clin Oncol 2005; 23: 3043-3051.
25. Chaudru V, Laud K, Avril MF, et al. Melanocortin-1 receptor (MC1R) gene variants and dysplastic nevi modify penetrance of CDKN2A mutations in French MM-prone pedigrees. Cancer Epidemiol Biomarkers Prev. 2005; 14: 2384-2390.
26. Kadekaro AL, Wakamatsu K, Ito S, Abdel-Malek ZA,. Cutaneous photoprotection and MM susceptibility: reaching beyond melanin content to the frontiers of DNA repair. Front Biosci 2006; 11: 2157-2173.
27. Yang HP, Chen K, Ju M, Chang BZ, Wang LY, Gu H,. A study of the way in which dermatologists and photosensitive patients apply sunscreen in China. Photodermatol Photoimmunol Photomed 2009; 25: 245-249.
28. Szepietowski JC, Nowicka D, Reich A, Melon M,. Application of sunscreen preparations among young Polish people. J Cosmet Dermatol. 2004; 3: 69-72.
29. Gilaberte Y, Gonzalez S,. Update on photoprotection. Actas Dermosifilogr 2010; 101: 659-672.
30. Abdel-Malek ZA, Knittel J, Kadekaro AL, Swope VB, Starner R,. The Melanocortin 1 receptor and the UV response of human melanocytes-A shift in paradigm. Photochem Photobiol 2008; 84: 501-508.
31. Bishop DT, Demenais F, Iles MM, et al. Genome-wide association study identifies three loci associated with melanoma risk. Nat Genet 2009; 41: 920-925.